Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이정연 | * |
dc.contributor.author | 강지은 | * |
dc.contributor.author | 금민정 | * |
dc.date.accessioned | 2022-02-14T16:31:37Z | - |
dc.date.available | 2022-02-14T16:31:37Z | - |
dc.date.issued | 2021 | * |
dc.identifier.issn | 1424-8247 | * |
dc.identifier.other | OAK-31000 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/260469 | - |
dc.description.abstract | Doxorubicin and cyclophosphamide (AC)-based chemotherapy has been a standard regimen for early-stage breast cancer (ESBC) with an intermediate risk (10-20%) of febrile neutropenia (FN). Secondary prophylaxis of granulocyte colony-stimulating factor (G-CSF) is considered in patients receiving AC-based chemotherapy; however, relevant studies are limited. Here, we retrospectively reviewed the electronic medical records of 320 patients who completed adjuvant AC-based chemotherapy from September 2016 to September 2020. Approximately 46.6% of the patients developed severe neutropenic events (SNE) during AC-based chemotherapy. Secondary prophylaxis of G-CSF reduced the risk of recurrent SNE (p < 0.01) and the relative dose intensity (RDI) < 85% (p = 0.03) in patients who had experienced SNE during AC-based chemotherapy. Age & GE; 65 years (p = 0.02) and alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 60 IU/L (p = 0.04) were significant risk factors for RDI < 85%. The incidences of FN, grade 4 neutropenia, unscheduled hospitalization, and interruption to the dosing regimen were reduced in patients administered secondary prophylaxis with G-CSF (before vs. after administration: FN, 19.4% vs. 4.6%; grade 4 neutropenia, 86.1% vs. 14.8%; unscheduled hospitalization, 75.9% vs. 11.1%; interruption to the dosing regimen, 18.5% vs. 8.3%). This study indicated the importance of active intervention of G-CSF use to prevent recurrent SNE and improve clinical outcomes in patients with breast cancer who receive AC-based chemotherapy. | * |
dc.language | English | * |
dc.publisher | MDPI | * |
dc.subject | secondary prophylaxis | * |
dc.subject | granulocyte colony-stimulating factor | * |
dc.subject | breast cancer | * |
dc.subject | neutropenia | * |
dc.subject | adjuvant chemotherapy | * |
dc.subject | doxorubicin | * |
dc.subject | cyclophosphamide | * |
dc.title | Clinical Outcomes of Secondary Prophylactic Granulocyte Colony-Stimulating Factors in Breast Cancer Patients at a Risk of Neutropenia with Doxorubicin and Cyclophosphamide-Based Chemotherapy | * |
dc.type | Article | * |
dc.relation.issue | 11 | * |
dc.relation.volume | 14 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.journaltitle | PHARMACEUTICALS | * |
dc.identifier.doi | 10.3390/ph14111200 | * |
dc.identifier.wosid | WOS:000726006000001 | * |
dc.author.google | Choi, Jae Hee | * |
dc.author.google | Geum, Min Jung | * |
dc.author.google | Kang, Ji Eun | * |
dc.author.google | Park, Nam Gi | * |
dc.author.google | Oh, Yun Kyoung | * |
dc.author.google | Rhie, Sandy Jeong | * |
dc.contributor.scopusid | 이정연(57191753089) | * |
dc.contributor.scopusid | 강지은(57155481300) | * |
dc.date.modifydate | 20240220111424 | * |